Invasive procedures like PET & Spinal Tap have an impact on patient willingness to participate in a clinical trial.
Imeka’s non-invasive technology adds a positive value to patient’s desire to participate in a clinical trial.
Furthermore, diffusion MRI can generate AFD (Apparent Fiber Density) markers that correlate negatively with NFL (Neurofilament light), enabling a more precise tracking of patient’s changes, without needing biological samples.
Improve subject selection by tracking through white matter hyperintensity lesions. This helps with assessing if structure is left or not.
Another improvement for your trials:
Bundle segmentation enables better drug targeting in specific white matter areas. This is better and more specific than whole brain measures.
Free-water is a localized proxy sensitive to neuroinflammation which can be used for better drug selection and drug effect assessment. This proxy correlates with Beta Amyloid PET gold standard.